NX-1607 is under clinical development by Nurix Therapeutics and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase I drugs for Adenocarcinoma Of The Gastroesophageal Junction have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NX-1607’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NX-1607 overview

NX-1607 is under development for the treatment of solid tumors including melanoma, epithelial ovarian cancer, gastric cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, metastatic castration resistant prostate cancer, diffuse large b-cell lymphoma with Richter transformation, cervical cancer, metastatic colorectal cancer, fallopian tube cancer, peritoneal cancer, metastatic urothelial cancer, malignant pleural mesothelioma and adenocarcinoma of the gastroesophageal junction. It is administered by oral route. It act by targeting casitas B lineage lymphoma proto-oncogene b (CBL-b). The drug candidate is developed based on DEligase platform.

Nurix Therapeutics overview

Nurix Therapeutics, formerly Nurix Inc, is a biopharmaceutical company that discovers, develops and commercializes small molecule drugs to treat cancer and autoimmune diseases. It is investigating NX-2127, a Bruton’s tyrosine kinase (BTK) inhibitor against B-cell malignancies; NX-5948 drug for the treatment of B-cell malignancies and autoimmune diseases. Nurix employs DELigase platform technology to modulate targeted proteins and also destroy disease-causing proteins by harnessing the activity of specific E3 ligases. The company works in collaboration with Sanofi and Gilead Sciences to develop its products. Nurix is headquartered in San Francisco, California, the US.

For a complete picture of NX-1607’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.